Changeflow GovPing Pharma & Drug Safety Azabicyclo Chromenone Derivatives for RNA Splic...
Routine Notice Added Final

Azabicyclo Chromenone Derivatives for RNA Splicing Modulation in Neurological Diseases

Favicon for changeflow.com EPO Patent Bulletin - Organic Chemistry (C07D)
Published
Detected
Email

Summary

The European Patent Office published patent EP4192454A1, granted to Skyhawk Therapeutics, Inc., covering 6-(6-((8-azabicyclo[3.2.1]octan-3-yl)amino)-1,2,4-triazin-3-yl)-7-hydroxy-4H-chromen-4-one derivatives. The patent claims compositions and methods for modulating RNA splicing for the treatment of neurological diseases. The patent names three inventors and is designated across 38 European contracting states.

What changed

The EPO published European Patent Application EP4192454A1 for Skyhawk Therapeutics, covering azabicyclo chromenone derivatives that modulate RNA splicing. The compound compositions are directed toward treating neurological diseases. IPC classifications span heterocyclic compounds (C07D 451/04, C07D 498/08) and pharmaceutical preparations (A61K 31/53, A61K 31/439). The patent also covers uses for neurological conditions (A61P 25/00) and oncology (A61P 35/00).

Pharmaceutical companies developing RNA splicing modulators for neurological applications should conduct freedom-to-operate analyses before entering the European market. Companies with competing technologies in this therapeutic space should evaluate potential patent conflicts. The patent provides exclusive rights in 38 EPO contracting states including all major EU markets, with validity running from the filing date.

Archived snapshot

Apr 2, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

6-(6-((8-AZABICYCLO[3.2.1]OCTAN-3- YL)AMINO)-1,2,4-TRIAZIN-3-YL)-7-HYDROXY-4H-CHROMEN-4-ONE DERIVATIVES FOR MODULATING SPLICING FOR THE TREATMENT OF NEUROLOGICAL DISEASES

Publication EP4192454A1 Kind: A1 Mar 25, 2026

Applicants

Skyhawk Therapeutics, Inc.

Inventors

LUZZIO, Michael, LUCAS, Brian, WANG, Tiansheng

IPC Classifications

C07D 451/04 20060101AFI20251202BHEP C07D 498/08 20060101ALI20251202BHEP A61K 31/53 20060101ALI20251202BHEP A61K 31/439 20060101ALI20251202BHEP A61P 25/00 20060101ALI20251202BHEP A61P 35/00 20060101ALI20251202BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Named provisions

Azabicyclo Chromenone Derivatives RNA Splicing Modulation Neurological Disease Treatment

Get daily alerts for EPO Patent Bulletin - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.

Last updated

Classification

Agency
EPO
Published
March 25th, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP4192454A1

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent Protection Pharmaceutical Development
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Healthcare Pharmaceuticals

Get alerts for this source

We'll email you when EPO Patent Bulletin - Organic Chemistry (C07D) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.